24.57
-1.92%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mayinglong Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 600993.SS. It has been listed since 17 May 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.87bn and net income of CN¥581.5m. At that date it held total assets of CN¥5.44bn and shareholders' equity of CN¥4.38bn.
Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Wuhan, Hubei. The company went IPO on 2004-05-17. The firm's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The firm also provides specialty drugs. The firm is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The firm distributes its products mainly in domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 May 2004
- Employees
- 3,241
- Website
- mayinglong.cn/index.html ↗
Leadership
Pay as last reported
- Mr. Ping ChenChairman of the Board, since 1993CN¥120,000
- Mr. Guangxiang SuVice Chairman of the Board, since 2005CN¥886,000
- Mr. Tao MaoChief Financial Officer
- Mr. Youzhang XiaGeneral Manager, Director, since 2010CN¥1.1m
- Mr. Pingan LiuDeputy General ManagerCN¥108,000
- Mr. Zhiqi SongDeputy General ManagerCN¥968,000
- Mr. Zhengjun TianDeputy General Manager, since 2019CN¥826,000
- Ms. Yu BaiAssistant General ManagerCN¥772,000
- Mr. Wei ZhangAssistant General ManagerCN¥748,000
- Mr. Daonian ZhouAssistant General ManagerCN¥800,000
- Ms. Qian MaSecretary of the Board, Assistant General ManagerCN¥608,000
- Mr. Kuangguo ChenDirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mayinglong Pharmaceutical Group employs 3,241 full-time employees in Wuhan, Hubei.
- Mayinglong BaBao eye cream products are distributed domestically in China.
- The company manufactures hemorrhoid drugs including diosmin tablets and suppositories.
Weaknesses
- Mayinglong Pharmaceutical Group's products are limited to domestic Chinese markets.
- The company's business is focused on hemorrhoid, cough, and skin injury drugs.
- Mayinglong Pharmaceutical Group has no international distribution channels.
Opportunities
- Mayinglong Pharmaceutical Group can expand into international markets for pharmaceutical products.
- The company can develop new specialty drugs for global health care needs.
- Mayinglong BaBao eye cream has potential for international brand recognition.
Threats
- Mayinglong Pharmaceutical Group faces competition from domestic pharmaceutical companies in China.
- The company's reliance on domestic markets exposes it to local economic fluctuations.
- Mayinglong Pharmaceutical Group's product range is narrow compared to global pharmaceutical firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.